Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in patients with functional mitral regurgitation  by Godino, Cosmo et al.
IJC Heart & Vasculature 11 (2016) 90–98
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureImpact and evolution of right ventricular dysfunction after successful
MitraClip implantation in patients with functional mitral regurgitationCosmo Godino a,⁎, Anna Salerno a, Michela Cera a, Eustachio Agricola a, Gabriele Fragasso a, Isabella Rosa a,
Michele Oppizzi a, Alberto Monello a, Andrea Scotti a, Valeria Magni a, Matteo Montorfano a,
Alberto Cappelletti a, Alberto Margonato a, Antonio Colombo a,b
a Cardio-Thoracic-Vascular Department, San Raffaele Scientiﬁc Institute, Milan, Italy
b EMO-GVM Centro Cuore Columbus, Milan, Italy⁎ Corresponding author at: Cardio-Thoracic-Vascu
Scientiﬁc Institute, Via Olgettina 60, 20132 Milan, Italy.
E-mail address: cosmogodino@gmail.com (C. Godino)
http://dx.doi.org/10.1016/j.ijcha.2016.05.017
2352-9067/© 2016 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 27 March 2016
Accepted 2 May 2016
Available online 9 May 2016Background: Right ventricular dysfunction (RVdysf) is a predictor of poor outcome in patients with heart failure
and valvular disease. The aim of this study was to evaluate the evolution and the impact of RVdysf in patients
with moderate–severe functional mitral regurgitation (FMR) successfully treated with MitraClip.
Methods and results: From October 2008 to July 2014, 60 consecutive high surgical risk FMR patients were
evaluated and stratiﬁed into two groups: RVdysf group (TAPSE b 16 mm and/or S′TDI b10 cm/s, 21 patients)
and No-RVdysf group (38 patients). The overall mean age of patients was 73 ± 8 (83% male). Ischemic FMR eti-
ologywas present in 67%. Mean LVEFwas 30± 10%. Overall mean time follow-upwas 565± 310 days. The only
signiﬁcant difference between the two groupswas a greater prevalence of stroke, ICD and use of aldosterone an-
tagonist in RVdysf group. Acute procedural success was achieved in 90% of patients. At 6-month echo-matched
analysis signiﬁcant RV function improvement was observed in patients with baseline RVdysf (TAPSE 15 ± 3.0
vs. 19± 4.5, p= 0.007; S′TDI 7± 1.2 vs. 11± 2.8, p b 0.0001; baseline vs. 6-month, respectively). Themean im-
provement in the 6-min walking test was signiﬁcant in both groups (120 and 143 m, RVdysf and No-RVdysf
groups, respectively). At Kaplan–Meier analysis, the presence of RVdysf did not affect the outcome in terms of
freedom from composite efﬁcacy endpoint.
Conclusions: This study shows that successful MitraClip implantation in patientswith FMR and concomitant right
ventricular dysfunction yields signiﬁcant improvement of RV function at mid-term follow-up. Further data on
larger population will be required to conﬁrm our observations.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Heart failure1. Introduction
Mitral regurgitation (MR) represents the second most common val-
vular disease in Europe [1]. This pathology evolves over many years,
allowing the heart to adapt to a chronic volume overload, leading to sig-
niﬁcant and complex hemodynamic and structural changes. In chronic
severe MR, left ventricular remodeling leads to the development of
signiﬁcant pulmonary hypertension in almost half of the patients [2,3].
The increase in right ventricular (RV) afterload at ﬁrst induces right
atrial and RV remodeling, and afterwards leads to RV dysfunction. RV
dysfunction represents a strong and independent predictor of mortality
in left ventricular ischemic and non-ischemic heart failure (HF) [4–10].
Alternate effects of surgical mitral valve repair or replacement on
preexisting RV dysfunction have been reported in different publishedlar Department, San Raffaele
.
land Ltd. This is an open access articlseries of patients [11–18] Percutaneous mitral valve repair with
MitraClip has been shown to be associated with a favorable clinical out-
come and left and right ventricular reverse remodeling in high-risk pa-
tients with severe MR [19–22]. In the present study we evaluated the
impact and the evolution of pre-existing RV dysfunction in high-risk
functional MR (FMR) patients after successful MitraClip implantation.
2. Methods
2.1. Study population and clinical endpoints
From October 2008 to July 2014, 60 consecutive MitraClip treated
patients were evaluated at San Raffaele Hospital and at EMO-GVM
Centro Cuore Columbus, Milan, Italy. The MitraClip procedure was con-
sidered in patients with symptomatic severe FMR who fulﬁlled the
echocardiographic criteria of eligibility and judged inoperable or at
high surgical risk by a ‘heart team’, and had a life expectancy greater
than 1 year (according to the ESC/EACTS 2012 recommendation classe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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possible risk and procedural beneﬁt of MitraClip procedure and writtenTable 1
Preoperative clinical characteristics of patients with FMR stratiﬁed for RV dysfunction (RVdysf
FMR patients (n = 60) No-R
Clinical characteristics (%)
Age, years 73 ± 8 73.6
Proportion aged N80 years 9 (15) 7 (18
Male gender 50 (83) 31 (8
BMI, kg/m2 25 ± 3.6 25 ±
BSA, m2 1.8 ± 0.19 1.8 ±
Hypertension 43 (72) 29 (7
Hypercholesterolemia 32 (53) 21 (5
Previous/Current smoker 27 (45) 16 (4
Diabetes mellitus (DM) 18 (30) 10 (2
Insulin-dependent DM 10 (17) 5 (13
Moderate/Severe COPD 19 (32) 11 (2
CRF⁎ 36 (60) 21 (5
Atrial ﬁbrillation 21 (35) 11 (2
Logistic EuroSCORE 27.2 ± 20.5 23.8
Logistic EuroSCORE N25 30 (50) 16 (4
STS score mortality 7.9 ± 8.5 8.0 ±
Advanced congestive HF 21 (35) 10 (2
§6-MWT, m 293 ± 97 290 ±
Ischemic FMR etiology 40 (67) 24 (6
NYHA functional class (III-IV) 42 (70) 27 (7
Pulmonary hypertension⁎⁎⁎ 11 (18) 7 (18
Coronary artery disease 42 (70) 24 (6
Three-vessel disease 22 (37) 14 (3
Chronic stable angina 9 (15) 5 (13
Previous pulmonary edema 28 (47) 16 (4
Previous AMI 38 (63) 21 (5
Previous PCI 31 (52) 18 (4
Previous CABG 17 (28) 10 (2
Peripheral vascular disease 13 (22) 6 (16
Previous stroke 3 (5) 0 (0)
Laboratory analysis
NT-pro-BNP, pg/ml 9004 ± 15958 8323
NT-pro-BNP ≥10.000 pg/ml 10 (17) 4 (10
Sodium, mEq/l 138 ± 4 138 ±
Hemoglobin, gr/dl 11.8 ± 1.8 11.9
RDW N15% 37 (62) 24 (6
RDW, % 16.1 ± 2.1 15.9
Creatinine, mg/dl 1.06 ± 0.7 1.7 ±
Bilirubin, mg/dl 0.86 ± 0.5 0.78
AST, units/L 59 ± 224 80 ±
ALT, units/L 49 ± 165 67 ±
Treatment history (%)
Cardiovascular medication
Loop diuretic 56 (93) 34 (8
Loop diuretic, mg 138 ± 111 144 ±
Aldosterone antagonist 29 (48) 14 (3
Aldosterone antagonist, mg 19.5 ± 16.6 14.9
Beta-blocker 47 (78) 31 (8
CCB 3 (5) 3 (8)
ACE-I/ARB 31 (52) 21 (5
Ivabradine 6 (10) 3 (8)
Digoxin 9 (15) 6 (16
Cardioaspirin 39 (60) 25 (6
Dual antiplatelet therapy 17 (28) 11 (2
Oral anticoagulant therapy 22 (37) 12 (3
Electrical therapy
ICD 36 (60) 19 (5
CRT-D 11 (18) 5 (13
CRT-PM 10 (17) 5 (13
Data are presented as absolute numbers and percentages (for categorical variables) or mean v
Student's unpaired t-test for continuous data; Chi-square test for categorical data.
AMI = acute myocardial infarction; ACE = angiotensin converting enzyme; ARB = angiote
BMI= bodymass index; BSA= body surface area; CABG= coronary artery bypass grafting; CC
lator; CRT-PM= cardiac resynchronization therapy without deﬁbrillator; COPD = chronic ob
York Heart Association. NT-pro-BNP = N-terminal protype-brain natriuretic peptide; PCI = p
Bold numbers indicate signiﬁcance at p value b 0.05.
⁎Chronic renal failure (CRF) was deﬁned as an estimated glomerular ﬁltration rate (eGFR) b60
⁎⁎Severe pulmonary hypertension was deﬁned as a pulmonary systolic pressure ≥60 mm Hg a
§6-MWT= six minutes walking test, available in 34 patients (60% of patients).consentwas obtained for theprocedure, data collection, and subsequent
analysis and publication. The studywas approved by the Hospital Ethics).
Vdysf group (n = 38) RVdysf group (n = 22) p value
± 7 72 ± 8 0.478
) 2 (9) 0.329
2) 19 (86) 0.632
2.8 24 ± 4 0.651
0.18 1.8 ± 0.21 0.655
6) 14 (64) 0.294
5) 11 (50) 0.662
2) 11 (50) 0.554
6) 8 (36) 0.413
) 5 (23) 0.338
9) 8 (36) 0.647
5) 15 (68) 0.325
9) 11 (50) 0.103
± 18 33 ± 23 0.101
2) 14 (64) 0.089
8.7 7.7 ± 8.4 0.883
6) 11 (50) 0.093
92 298 ± 112 0.815
3) 16 (73) 0.449
1) 15 (68) 0.815
) 4 (18) 0.916
3) 16 (73) 0.115
7) 8 (36) 0.970
) 4 (18) 0.606
2) 12 (54) 0.355
5) 17 (77) 0.119
7) 13 (59) 0.384
6) 7 (32) 0.658
) 7 (32) 0.146
3 (14) 0.020
± 16258 10206 ± 15833 0.702
) 6 (27) 0.077
4 138 ± 4 0.967
± 1.7 11.7 ± 1.8 0.752
3) 13 (59) 0.755
± 2.0 16.3 ± 2.1 0.551
0.7 1.6 ± 0.6 0.600
± 0.55 0.99 ± 0.4 0.172
283 24 ± 8 0.364
208 20 ± 9 0.309
9) 22 (100) 0.170
113 128 ± 111 0.603
7) 15 (68) 0.024
± 15.3 23.4 ± 17.1 0.180
2) 16 (73) 0.308
0 (0) 0.170
5) 10 (45) 0.213
3 (14) 0.497
) 3 (14) 0.778
6) 14 (64) 0.708
9) 6 (27) 1.000
2) 10 (45) 0.317
0) 17 (77) 0.038
) 6 (27) 0.173
) 5 (23) 0.234
alue ± SD (for continuous variables) unless otherwise speciﬁed.
nsin II receptor blocker; AST= aspartate aminotransferase; ALT= alanine transaminase;
B= Calcium channel blockers; CRT D= cardiac resynchronization therapywith deﬁbril-
structive pulmonary disease; ICD = implantable cardioverter deﬁbrillator; NYHA = New
ercutaneous coronary intervention; RDW= red cell distribution with.
ml/min/1.73 m2.
s estimated by doppler echocardiography.
Table 2
Preoperative echocardiographic features.
FMR
patients
(n = 60)
No-RVdysf
group
(n = 38)
RVdysf
group
(n = 22)
p value
Left ventricle and atrium
LVEDD, mm 66.8 ± 9.2 66.1 ± 9.4 67.8 ± 9.1 0.507
LVEDD N55 mm 51 (85) 32 (84) 19 (86) 0.851
LVESD, mm 56.1 ± 10.2 55.6 ± 10.1 57.0 ± 11.0 0.772
LVEDV, ml 210 ± 78 210 ± 85 211 ± 66 0.954
LVESV, ml 147 ± 69 146 ± 77 148 ± 55 0.914
LVEF, % 30 ± 10 31 ± 11 27 ± 7 0.097
LVEF ≤35% 44 (73) 25 (66) 19 (86) 0.082
MR 4+ (severe) 50 (83) 31 (82) 19 (86) 0.628
Eccentric mitral
regurgitation jet
13 (22) 8 (21) 5 (23) 0.950
Tenting area, cm2 2.93 ±1.38 3.12 ± 1.86 2.79 ± 1.07 0.700
Coaptation depth, mm 12.63 ± 4.87 11.98 ± 3.29 13.51 ± 6.44 0.331
Coaptation length, mm 2.25 ± 1.98 2.55 ± 2.07 1.87 ± 1.65 0.293
Restrictive transmitral
ﬁlling patterns
22 (37) 13 (34) 9 (41) 0.861
Atrium volume, ml 134 ± 46 135 ± 53 131 ± 34 0.754
Right ventricle and atrium
RV basal diameter, mm 40 ± 8 38 ± 7 44 ± 8 0.048
RV basal diameter N42 mm 12 (20) 6 (16) 6 (27) 0.052
TR grade N2+ 15 (25) 8 (21) 7 (32) 0.428
sPAP, mmHg 50 ± 16 49 ± 17 51 ± 14 0.626
sPAP N60 mmHg 12 (20) 7 (18) 5 (23) 0.737
TAPSE, mm 19.3 ± 4.2 21.3 ± 3.4 15.5 ± 3.0 0.000
TAPSE b16 mm 12 (20) 0 (0) 12 (54) 0.000
SʹTDI, cm/s 10 ± 2.5 11.7 ± 1.4 7.3 ± 1.2 0.000
SʹTDI b10 cm/s 21 (35) 0 (0) 21 (95) 0.000
LVEDD= left ventricular end diastolic diameter, LVESD= left ventricular end systolic di-
ameter, LVEDV= left ventricular end diastolic volume, LVESV= left ventricular end sys-
tolic volume, LVEF = left ventricular ejection fraction, LA vol = left atrial volume; MR=
mitral regurgitation, RV= right ventricle, TR= tricuspid regurgitation, PAP=pulmonary
arterial pressure, TAPSE = tricuspid annular plane systolic excursion, SʹTDI = systolic
wave with tissue Doppler imaging.
Bold numbers indicate signiﬁcance at p value b 0.05.
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patients had symptomatic moderate-to-severe or severe FMR despite
optimal medical therapy. Prior to implantation, all patients underwent
coronary angiography to exclude relevant coronary artery disease ne-
cessitating revascularization. Furthermore, patients underwent trans-
thoracic and transoesophageal echocardiography to quantify MR and
to judgemorphological suitability forMitraClip implantation. According
to the EVEREST II protocol [23], acute procedural success (APS) was de-
ﬁned as implantation of at least one clip and post-procedural MR
≤2+. Advanced congestive heart failure (HF) deﬁned patients with
NYHA class III-IV in spite of maximal medical treatment and
concomitant presence of LVEDD N70 mm and/or LVEF b20% and/or
NT-proBNP N10,000 pg/ml. The transthoracic and transoesophageal
echocardiograms were obtained using commercially available ultra-
sound diagnostic systems (Philips IE 33, Royal Philips Electronics,
Amsterdam, The Netherlands, or Vivid 7 and Vivid E9, GE Medical Sys-
tems, Milwaukee, WI, USA) by two experienced investigators (MO and
EA), according to current ESC/ACC guidelines [21]. Assessment of RV
function was performed with the apical four-chamber and parasternal
RV inﬂow and outﬂow tract views. The following quantitative conven-
tional indices were measured: tricuspid annular plane systolic excur-
sion (TAPSE), peak systolic velocity at the junction of the RV free wall
and the tricuspid annulus, assessed with pulsed tissue Doppler imaging
(S′TDI). Systolic pulmonary artery pressure (sPAP) was calculated from
tricuspid regurgitation maximum pressure gradient by use of the
modiﬁed Bernoulli equation, with the addition of an estimate of central
venous pressure. Tricuspid regurgitation gradewas evaluated according
to a visual scale ranging from 1 to 4.
All FMRpatientswere stratiﬁed for RVdysf at baseline aswithNo/Mild
RV dysfunction, (No-RVdysf group: TAPSE ≥16 mm and/or S′TDI ≥10 cm/
s) orwithmoderate/severe RV dysfunction, (RVdysf group: TAPSE b16mm
and/or S′TDI b10 cm/s), according to the European Society of Echocardi-
ography guidelines [24]. In case of discrepancy, the S′TDI was utilized as
the discriminant value (90% sensitivity and 85% speciﬁcity to identify
the presence of RVdysf) [25]. Patients were excluded if the morphology
of the mitral valve made MitraClip implantation technically impossible
or unlikely beyond the classical EVEREST criteria (i.e. short or calciﬁed
posterior leaﬂet without the possibility of leaﬂet grasping or moderate
to severemitral stenosis). All patients underwent blood sampling for rou-
tine complete blood count, basic metabolic panel, liver function test, NT-
proBNP (Roche NT-proBNP assay) prior to MitraClip implantation. A
6 min walk test (6-MWT) was performed in eligible patient.
2.2. Study endpoints
The primary endpoint of this study was the echocardiographic evalu-
ation of RV function at 6-month follow-up after successfulMitraClip im-
plantation (echo-matched analysis). Additional pre-speciﬁed secondary
endpointswere: A) composite efﬁcacy endpoint [cardiac death, hospital-
izations for acute decompensated heart failure, LVAD (left ventricular
assist device) implantation and need for conventional mitral valve
surgery after MitraClip (up to 24-month follow-up)]; B) New York
Heart Association (NYHA) heart failure class and C) 6 min walking test
(6-MWT) variation (at 6-month follow-up).
2.3. Mitraclip implantation procedure
The endovascular edge-to-edge mitral valve repair procedure has
been previously described [23]. All procedures were performed using
a 24 Fr MitraClip device using CDS01 or CDS02 (Abbott Vascular, Santa
Clara, CA, USA). All clips were implanted under general anesthesia and
ﬂuoroscopic and transoesophageal echocardiographic control. Hemo-
stasis was achieved by compression of the femoral vein for 5–10 min
soon after ﬁgure-of-eight suture. Patients were transferred to our
intermediate care unit or, if necessary, intensive care unit.2.4. Clinical and echocardiographic follow-up
Before discharge, all patients were evaluated with NYHA class as-
sessment, 6-MWT, NT-pro-BNP measurement and echocardiography.
After MitraClip implantation, patients were prospectively followed up
at 1, 6 and up to 24 months. Clinical evaluation of NYHA class, blood
sampling for NT-pro-BNP, and echocardiography were performed at
every follow-up visit. When feasible, a 6-MWT was performed. Three
and nine patients declined to attend, respectively, 6 and 24months clin-
ical follow-up examination after implantation. Nevertheless, in these
cases, follow-up data was obtained by telephone interviews. Echocardi-
ographywas performed in 53 eligible patients at 6-months (98%) and in
49 patients after 24-month (91%).
2.5. Statistical analysis
Continuous variables were reported as mean ± standard deviation
(SD) ormedian (inter-quartile range, IQR) and comparedwith Student's
t test or Mann–Whitney or Wilcoxon tests, based on the normality
(Kolmogorov–Smirnov goodness-of-ﬁt test) of thedata. Categorical var-
iables (as frequencies or percentage) were compared with χ2 test with
Yates correction for continuity or the Fisher exact test as appropriate
for the available data [26]. Differences between matched baseline and
6-month follow-up echocardiographic data (primary endpoint) and
NYHA class/6-MWT data (secondary endpoints) were analyzed using
thematched-pair t-test orWilcoxon signed-rank test, according to nor-
mality of distribution. Event-free survival during follow-upwas evaluat-
ed according to the unadjusted Kaplan–Meier method and survival
among groups was compared using log-rank test (Cox–Mantel test).
Clinical follow-up was censored at the date of last follow-up or up to
Table 3
Procedural characteristics, complications and In-hospital outcome.
FMR
patients
(n = 60)
No-RVdysf
group
(n = 38)
RVdysf
group
(n = 22)
p value
Acute procedural success (APS) 54 (90) 34 (89) 20 (91) 0.858
Procedure time, min 97 ± 90 108 ± 87 70 ± 35 0.326
Fluoroscopy duration, min 50 ± 45 56 ± 53 38 ± 22 0.202
Number of clip implanted 1.63 ± 0.62 1.64 ± 0.63 1.62 ± 0.59 0.908
Clip embolization 0 0 0 NA
Inotropic support 20 (33) 11 (29) 9 (41) 0.348
IABP support 8 (13) 5 (13) 3 (14) 0.967
In-hospital outcome
Overall mortality 3 (5) 2 (5) 1 (4) 0.897
Cardiac mortality 2 (3) 1 (3) 1 (4) 0.695
Acute kidney injury 1 (2) 0 (0) 1 (4) 0.187
Need for CVVH 1 (2) 0 (0) 1 (4) 0.176
Major infection/sepsis 2 (3) 1 (3) 1 (4) 0.695
Stroke 0 0 0 NA
AMI 0 0 0 NA
Partial clip detachment 1 (2) 1 (3) 0 0.441
Need for blood transfusion 2 (3) 0 (0) 2 (9) 0.132
LOS, days 7.6 ± 4.8 7.9 ± 5.4 7.0 ± 3.3 0.465
CVVH= continuous venous-venous hemoﬁltration; AMI = acute myocardial infarction;
LOS = length of stay.
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whowere lost to follow-upwere censored at the timeof the last contact.
Cox proportional hazards methods were used to estimate the indepen-
dent effect of multiple independent variables on the risk of composite
efﬁcacy endpoint (secondary endpoint). To avoid multicollinearity, a
“low-noise model” has been researched in which each predictor vari-
able correlate at most only minimally with the other. Selection of the
variables included in the multivariate model was done with backward
elimination (Wald statistic, conﬁrmed using forward and stepwise se-
lection) based on covariates listed in Tables 1 and 2. Only the covariates
that were signiﬁcantly associated with the risk of composite efﬁcacy
endpoint at univariate analysis (p b 0.05 for model inclusion and
p N 0.10 for exclusion) and that considered clinically relevant were in-
cluded, and the convention of limiting the number of independent var-
iables to 1 for every 10 events was followed [27,28]. The proportional
hazards assumption was checked both graphically and by hypothesis
testing. Graphical examination was done using a log-cumulative hazard
plot. Linearity was checked graphically using the smoothed martingale
residuals from the null model plotted against the covariate variables.
The results are reported as adjusted hazard ratios (HRs) with associated
95% Conﬁdence Intervals (CI). Two-side p-values b0.05 were consid-
ered statistically signiﬁcant. The statistical analyses were performed
using SPSS 16.0.2 (SPSS Inc., Chicago, IL, USA) and NCSS 2007 (NCSS,
Kaysville, UT, USA). Kaplan–Meier survival curves were generated
with the use of GraphPad Prism software (version 4; GraphPad, Inc.,
San Diego, CA).
3. Results
The principal baseline characteristics of the overall population of pa-
tients with FMR (60 patients) are reported in Table 1. Brieﬂy, the meanFig. 1. Study ﬂage of patients was 73±8 (15%were N80 years old) and themajority of
themwere male (83%). Most patients had an increased surgical mortal-
ity risk as assessed by the logistic EuroSCORE (27.2 ± 20.5) and STS
score (7.9 ± 8.5). 30 patients (50%) had a logistic EuroSCORE N20 and
were thus considered very high risk patients for surgery. Ischemic
FMR etiology was present in 67% of cases. 42 patients (70%) were in
NYHA class III-IV. Preoperative echocardiographic features are reportedow-chart.
Table 4
Echo-matched 6-month analysis after successful MitraClip implantation in all eligible FMR patients stratiﬁed for RV dysfunction (RVdysf).
FMR patients (n = 53) No-RVdysf group (n = 33) RVdysf group (n = 20)
Baseline 6-Month p value Baseline 6-Month p value Baseline 6-Month p value
LVEDV, mm 217 ± 73 220 ± 66 0.697 216 ± 69 217 ± 56 0.880 218 ± 81 223 ± 82 0.707
LVESV, mm 155 ± 64 154 ± 64 0.880 152 ± 61 150 ± 55 0.739 159 ± 71 159 ± 77 0.980
LVEDD, mm 66 ± 7 64 ± 10 0.153 66 ± 6.5 63 ± 9.5 0.132 65 ± 10 64 ± 13 0.815
LVESD, mm 56 ± 15 54 ± 19 0.580 63 ± 14 64 ± 12 0.500 64 ± 12 65 ± 13 0.632
LVEF, % 30 ± 9 32 ± 10 0.066 32 ± 10 34 ± 10 0.083 28 ± 7 29 ± 10 0.446
LA volume, ml 139 ± 36 125 ± 54 0.139 138 ± 42 122 ± 31 0.094 141 ± 23 131 ± 81 0.623
MR grade 3.8 ± 0.6 2.0 ± 1.0 0.000 3.8 ± 0.6 2.1 ± 0.9 0.000 3.8 ± 0.5 1.6±1.0 0.000
sPAP, mmHg 49 ± 14 45 ± 13 0.039 46 ± 15 42 ± 13 0.045 53 ± 12 50 ± 13 0.035
TAPSE, mm 19 ± 4.5 21 ± 4 0.018 21 ± 3 22 ± 3 0.669 15 ± 3 19 ± 4.5 0.007
SʹTDI, cm/s 10 ± 2.5 11.5 ± 2.3 0.002 12 ± 1.2 12 ± 1.9 0.863 7 ± 1.2 11 ± 2.8 0.000
TR grade 2.1 ± 1.2 1.9 ± 1.0 0.302 1.9 ± 1.1 1.9 ± 0.9 0.840 2.4 ± 1.2 2 ± 1.1 0.088
RV diameter, mm 39 ± 9 41 ± 7 0.067 36 ± 8 39 ± 5.5 0.125 43 ± 10 45 ± 7 0.366
Bold numbers indicate signiﬁcance at p value b 0.05.
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at presentation. Of these, 10 patients (17%) had an NT-proBNP
N10.000 pg/mL. In most of these cases, MitraClip procedure was the
last treatment option before considering left ventricular assist devices
implantation as destination therapy. According to echocardiographic di-
agnostic criteria, we identiﬁed 38 patients (63%) with no/mild RV
dysfunction (No-RVdysf group) and 21 patients (37%) with moderate/
severe RV dysfunction (RVdysf group). Between the two patients'
groups there were no signiﬁcant differences in terms of clinical and
echocardiographic characteristics except for history of previous stroke,
implantable cardioverter-deﬁbrillator (ICD) and use of aldosterone an-
tagonist which were signiﬁcantly more often present in RVdysf group,
Tables 1 and 2.
3.1. Acute MitraClip results
Acute procedural success (APS) was achieved in 54 patients (90%),
Fig. 1. Four patients had post-proceduralMR N2+, in one case the proce-
dure was interrupted because of pericardial tamponade soon after tran-
septal puncture requiring percutaneous drainage. One patient had
retroperitoneal bleeding from femoral access site, which was managed
with manual compression and urgent embolization with ethylcellulose
microspheres. APS was obtained in all patients who implanted one
MitraClip (23 patients), in 94% of patientswho implanted twoMitraClips
(31 patients), in none of patients treatedwith ≥3MitraClips (5 patients).
Peri-procedural complications are listed in Table 3. Thirty-day mortality
rate was 5% (three deaths, all in-hospital): two cardiac-deaths (in pa-
tientswith end-stage heart failure) and one non cardiac-death (acute re-
spiratory distress syndrome in obstructive and restrictive lung disease).Fig. 2.Mitral regurgitation grade at baseline, discharge, 6 months and 12 months after Mitra
stratiﬁed for RV dysfunction (RVdysf, panel B).3.2. Echocardiographic outcome
Echocardiographic data at baseline and at 6-month follow-up in 53
eligible patients are reported in Table 4, (one patient was missing for
6-month echo-matched analysis). Between baseline and 6-month
follow-up, a persistent and signiﬁcant reduction of MR grade was ob-
served in all FMR patients and in the 2-subgroups, (Table 4 and Fig. 2,
panel A). No signiﬁcant differences were found in terms of LV end-
diastolic and end-systolic volumes and diameter, as well as LVEF, in
both groups (No-RVdysf and RVdysf). On the contrary, a signiﬁcant im-
provement of RV function was observed in the overall population. RV
function improvement was mainly driven by the cohort of patients
with baseline RVdysf (TAPSE 15 ± 3.0 vs. 19 ± 4.5, p = 0.007; S′TDI
7 ± 1.2 vs. 11 ± 2.8, p b 0.0001; baseline vs. 6-month follow-up,
respectively), andwas observed in 79% of patients with baseline RVdysf
(15/19 patients). In all patients, mean systolic pulmonary arterial pres-
sure (sPAP)was signiﬁcantly reduced at follow-up (49±14vs. 45±13,
baseline vs follow-up, p = 0.039), while tricuspid regurgitation grade
did not change signiﬁcantly (2.1 ± 1.2 vs. 1.9 ± 1.0, p = 0.302); how-
ever, a sub-analysis including only 16 patients with moderate to severe
tricuspid regurgitation (TR ≥ 2), showed a trend in reduction of TR grade
after MitraClip (2.9 ± 0.9 vs. 2.4 ± 1.0, p = 0.08). We did not ﬁnd
signiﬁcant differences in RV function improvement according to MR
etiology (ischemic vs. non-ischemic cardiomyopathy).
3.3. Clinical follow-up
Mid-term follow-up events are listed in Table 5. The overall mean
follow-up time was 565 ± 310 days (median 395 days). The durationClip implantation in all FMR patients (panel A) and at baseline and 6 months in patients
Fig. 4. Six-minute walk test distance at baseline, discharge, 6 months in all FMR patients
(panel A) and at baseline and 6 months in patients stratiﬁed for RV dysfunction (RVdysf,
panel B). Matched analysis available for 45 patients at 6-month.
Table 5
Clinical outcome in all eligible FMR patients.
FMR patients
(n = 57)
No-RVdysf
(n = 37)
RVdysf
(n = 20)
p value
Days follow-up 605 ± 310 671 ± 280 605 ± 322 0.553
All death 18 (32) 10 (27) 8 (40) 0.315
Cardiac death 15 (26) 7 (19) 8 (40) 0.085
Sudden cardiac death 5 (9) 1 (3) 4 (20) 0.031
AMI 0 0 0 1.000
Stroke 1 (2) 1 (3) 0 (0) 0.458
Bleeding 4 (7) 3 (8) 1 (5) 0.664
Re-hospitalization for HF 20 (35) 12 (32) 8 (40) 0.470
Need for LVAD implantation 2 (3) 2 (5) 0 (0) 0.294
Composite efﬁcacy endpoint 26 (46) 15 (40) 11 (55) 0.339
NYHA class improvement
1 or 2 class improvement 24 (42) 16 (43) 8 (40) 0.764
3 class improvement 6 (10) 4 (11) 2 (10) 0.910
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No-RVdysf groups. Signiﬁcant NYHA improvement of 1 or 2 functional
classes was observed in all patients and was persistent at 12-month
follow-up (Fig. 3, panel A), without difference within the 2 groups
(Fig. 3, panel B). The mean improvement in the 6-min walking test
was signiﬁcant in both groups (120 and 143 m, RVdysf and No-RVdysf
groups, respectively; Fig. 4). Six patients (10%) died between the ﬁrst
month and the end of the sixth month after discharge: 5 cardiac deaths
(4 due to refractory heart failure and 1 sudden death), 1 non-cardiac
death (bowel occlusion). During follow-up, 2 cases of partial clip de-
tachment were observed. Two patients received LVAD due to progres-
sive heart failure (median time period after MitraClip 185 days, IQR
45–240). One case of redo-procedure was performed successfully for
the patient with pericardial tamponade during the index procedure.
At Kaplan–Meier and Cox-regression analysis, the presence of RV dys-
function did not affect the outcome in patients with APS (ﬁnal MR ≤2)
in terms of freedom from composite efﬁcacy endpoint (47% vs. 63%,
RVdysf vs. No-RVdysf, respectively, p = 0.567), Fig. 5. Multivariable
Cox regression analysis was used to identify clinical independent
predictors of composite efﬁcacy endpoint in all patients. The adjusted
Cox proportional-hazard analysis identiﬁed advanced congestive HF
and Logistic EuroSCORE N25 as signiﬁcant independent predictors of
composite efﬁcacy endpoint (Table 6).Fig. 3.Distributions of NewYork Heart Association functional (NYHA) class at baseline, 6month
stratiﬁed for RV dysfunction (panel B). Matched analysis available for 57 patients at 6-month a4. Discussion
This retrospective, observational, unblinded study involving high
risk patientswith FMR shows that: 1) successfulMitraClip correction in-
duces RV function improvement at 6-month follow-up in a sizeable pro-
portion of patients; 2) RV dysfunction is not a predictor of unfavorables and 12months afterMitraClip implantation in all FMR patients (panel A) and in patients
nd 43 patients at 12-month.
Fig. 5. Kaplan–Meyer curves of Freedom from combined primary endpoint according to presence or not of RV dysfunction (RVdysf).
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signiﬁcantly the grade of tricuspid regurgitation in those patients with
baseline moderate to severe tricuspid regurgitation. Additionally, our
results conﬁrm a signiﬁcant and persistent reduction of FMR grade dur-
ing follow-up, which is associated to concomitant improvements in
NYHA functional class and six-minute walking test, as previously re-
ported [29–32].
This study conﬁrms previous observations reporting that reduction
in LV ﬁlling pressure obtained after MitraClip implantation yields a pos-
itive effect on the hemodynamic of the right sections. At 6-month echo-
matched analysis, signiﬁcant reduction in sPAP and signiﬁcant increase
in longitudinal RV systolic function (increase in TAPSE and RV S′TDI)
were observed in 79% of patients with baseline RV dysfunction. These
ﬁndings could be related to the fact that RV performance is inﬂuenced
by elevated sPAP, which is a common ﬁnding in severe chronic MR. Re-
duced or normalized sPAP after surgicalmitral valve repair could at least
in part be the mechanism of the observed improvement of RV impair-
ment in such patients [33,34]. In the present study, we did not observe
an overall positive left ventricular remodeling effect, as reported in
other experience [31,32,35]. However, an improvement of mean LVEF
(of at least N5%) at echo-follow-up was observed in 34% of patients
(17/53 echo-matched); these patients were different from patient
with no LVEF improvement only for signiﬁcantly lower baseline
LVEDV (183 ml vs. 234 ml, p = 0.039). It is plausible that a better left
ventricular functional outcome could be observed in a larger study
population. Right ventricle could be more sensible to volume overload
than left ventricle is, because of their anatomical structures. It is con-
ceivable that a reduction in volume overload could be initially beneﬁcial
for the right ventricle and then for LV. A longer follow up could show
changes in left ventricle function. As a matter of fact, in chronic MRTable 6
Predictors of composite efﬁcacy endpoint (Cox proportional-hazard analysis).
Univariate
analysis
(p value)
Multivariate
analysis
(p value)
HR (95% CI)
RVdysf 0.416 0.602 0.76 (0.2–2.1)
Chronic renal failure (CRF) 0.795 0.287 1.79 (0.6–5.2)
Logistic EuroSCORE N25 0.009 0.030 3.82 (1.1–12.8)
Advanced congestive HF 0.000 0.001 6.67 (2.1–20)
Acute procedural success (APS) 0.159 0.585 0.69 (0.1–2.5)
Bold numbers indicate signiﬁcance at p value b 0.05.and LV dysfunction, subclinical LV damage could be present well before
the appearance of LV function impairment [36,37]. Similarly, irrevers-
ible myocardial damage was likely already present in our study popula-
tion, in the context of severe MR and LV dysfunction. The lack of further
deterioration of LV function could therefore be considered as a thera-
peutic goal, even in absence of signiﬁcant improvement.4.1. RV dysfunction and outcome
RV outcome after MitraClip procedure is not yet clearly deﬁned [21,
22]. RV dysfunction (mainly due to impairment of the longitudinal
shortening of the ventricular ﬁbers) is the result of a complex interac-
tion between the remodeled and enlarged left ventricle and atrial, septal
performance, and sPAP in presence of signiﬁcantMR [4]. Different stud-
ies in this context have reported conﬂicting results. RV dysfunction has
been reported to be a strong predictor of poor cardiovascular and over-
all survival in patients with heart failure [10,17,39,38,40]. Conversely,
isolated tricuspid regurgitation has been associatedwith a poor progno-
sis, independent of age, biventricular systolic function, RV size, and dila-
tion of the inferior vena cava [41]. Ghio et al. observed that RV function
may be preserved despite elevated sPAP and that RV dysfunction may
be observed even in patients with normal sPAP [8]. On the other hand,
other studies have established an inverse relation between RV systolic
function and pulmonary arterial pressure [42]. A recent observation in-
dicates that RV dysfunction, but not signiﬁcant TR, is independently as-
sociated with late survival after left heart valve surgical procedure [43].
In fact, recurrence or new development of signiﬁcant tricuspid regurgi-
tation late after left heart valve surgical procedure is frequently found
and varies between 9% and 49% [44–46]. It can be speculated that in pa-
tients with severe right heart dysfunction, the highermean trans-mitral
pressure gradient determined byMitraClip acting as a “iatrogenic”mild
mitral stenosis, may prevent progressive dilation of LV, but it could fur-
ther overload an already malfunctioning right ventricle [47]. In our se-
ries of patients, the presence of RV dysfunction did not affect clinical
outcome in terms of composite efﬁcacy endpoint rate, which was not
signiﬁcantly higher compared to patient without RV dysfunction (63%
vs. 47%, p = 0.567, Fig. 4). In fact, RV dysfunction improved while TR
grade remained unchanged. On the other hand, the Cox proportional-
hazard analysis identiﬁed advanced congestive HF and Logistic
EuroSCORE N25 as the only signiﬁcant independent predictors of com-
posite efﬁcacy endpoint. Pre-existing RV dysfunction before mitral
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up. On this basis, surgical repair before the occurrence of biventricular
impairment has been advocated. The most plausible explanations of
our resultsmay be related,ﬁrst, to the follow-up analysis focused on pa-
tients with successful MitraClip procedure, second, to the mild baseline
RVdysfunction (TAPSE 15.5mm, S′TDI 7.3 cm/s) of theRVdysf group. Fi-
nally, we should also take into account thatmitral surgerymay generate
more myocardial damage than a MitraClip procedure. However, the ef-
fects of openheart surgery and extracorporeal circulation by themselves
couldwell play a crucial role on an already diseased RV, which is known
to be more vulnerable as compared to the left heart [48]. Recently,
Orban et al. [49], reported a signiﬁcantly higher rate of mortality in a
subgroup of patient with severe biventricular heart failure and high-
risk proﬁle (mean LVEF 19.8%, TAPSE 13 mm, Logistic EuroSCORE
31.1) and found RV dysfunction and pulmonary hypertension as predic-
tors of poor outcome (1-yearmortality of 77%). Additional explanations
for this difference compared to our results could be related to a different
patient selection (higher LVEF and smaller LVEDD in our patients) and
deﬁnition of procedural success.
The major limits of the present study are related to its observational
nature, relatively small sample size and lack of a reference standard for
RV functional evaluation (such asmagnetic resonance imaging or three-
dimensional echocardiography). Moreover, it reﬂects the initial experi-
ence of our center and thus the results must be regarded as hypothesis
generating and exploratory and require validation in further larger
studies.
4.2. Conclusions
This observational study shows that successful MitraClip implanta-
tion in patients with FMR and RV dysfunction yields signiﬁcant
improvement of RV function at mid-term follow-up. The presence of
RV dysfunction does not appear to be a predictor of unfavorable clinical
outcome in these patients. The minimally invasive approach of
MitraClip could have played a signiﬁcant role in avoiding the late
deterioration of RV function and occurrence of tricuspid regurgitation,
frequently observed after surgical mitral valve repair.
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